

Title (en)  
METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST

Title (de)  
VERFAHREN ZUR BEHANDLUNG VON MIT IMMUNTHERAPIE EINHERGEHENDER TOXIZITÄT UNTER VERWENDUNG EINES GM-CSF-ANTAGONISTEN

Title (fr)  
MÉTHODES DE TRAITEMENT DE TOXICITÉ LIÉE À UNE IMMUNOTHÉRAPIE AU MOYEN D'UN ANTAGONISTE DU GM-CSF

Publication  
**EP 3849572 A2 20210721 (EN)**

Application  
**EP 19860890 A 20190910**

Priority

- US 201862729043 P 20180910
- US 201816149346 A 20181002
- US 2018053933 W 20181002
- US 201816204220 A 20181129
- US 201916248762 A 20190115
- US 201916283694 A 20190222
- US 2019050494 W 20190910

Abstract (en)  
[origin: WO2020055932A2] Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) are provided. Also provided are methods for GM-CSF gene inactivation or GM-CSF knockout (KO) in a cell comprising targeted genome editing or GM-CSF gene silencing. Methods for preventing/treating immunotherapy-related toxicity, comprising administering to the subject CAR-T cells having a GM-CSF gene inactivation or GM-CSF knockout (GM-CSFk/o CAR-T cells), wherein the GM-CSF gene is inactivated or knocked out and/or a recombinant GM-CSF antagonist are provided. Methods for reducing a level of a cytokine or chemokine other than GM-CSF in a subject having immunotherapy-related toxicity comprising administering to the subject a recombinant hGM-CSF antagonist are provided. Also provided are methods for treating or preventing immunotherapy-related toxicity in a subject, comprising administering to the subject chimeric antigen receptor-expressing T-cells (CAR-T cells), the CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells). Methods for preventing or reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) to the subject, also are provided.

IPC 8 full level  
**A61K 35/17** (2015.01); **A61K 39/395** (2006.01); **A61K 39/44** (2006.01); **A61P 35/02** (2006.01); **C07K 16/24** (2006.01); **C07K 16/28** (2006.01); **C12N 5/0783** (2010.01)

CPC (source: EP IL KR)  
**A61K 31/7088** (2013.01 - KR); **A61K 35/17** (2013.01 - KR); **A61K 38/193** (2013.01 - EP IL KR); **A61K 39/001112** (2018.07 - KR); **A61K 39/4611** (2023.05 - EP IL KR); **A61K 39/4631** (2023.05 - EP IL KR); **A61K 39/464406** (2023.05 - EP IL); **A61K 39/464412** (2023.05 - EP IL KR); **A61K 39/464429** (2023.05 - EP IL); **A61K 48/005** (2013.01 - KR); **A61P 35/02** (2017.12 - EP IL KR); **C07K 16/243** (2013.01 - EP KR); **C07K 16/2866** (2013.01 - KR); **A61K 2039/505** (2013.01 - EP KR); **A61K 2039/55516** (2013.01 - EP IL KR); **A61K 2239/31** (2023.05 - EP IL KR); **A61K 2239/38** (2023.05 - EP IL KR); **A61K 2239/46** (2023.05 - KR); **A61K 2239/48** (2023.05 - EP IL); **C07K 2317/24** (2013.01 - EP KR); **C07K 2317/55** (2013.01 - EP KR); **C07K 2317/92** (2013.01 - EP)

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

DOCDB simple family (publication)  
**WO 2020055932 A2 20200319**; **WO 2020055932 A3 20200522**; **WO 2020055932 A9 20200409**; **WO 2020055932 A9 20200709**; AU 2019340662 A1 20210506; BR 112021004489 A2 20210720; CA 3111804 A1 20200319; CN 113164520 A 20210723; EP 3849572 A2 20210721; EP 3849572 A4 20220713; IL 281243 A 20210429; JP 2022517461 A 20220309; KR 20210075090 A 20210622; MX 2021002856 A 20210528; SG 11202102317P A 20210429

DOCDB simple family (application)  
**US 2019050494 W 20190910**; AU 2019340662 A 20190910; BR 112021004489 A 20190910; CA 3111804 A 20190910; CN 201980073595 A 20190910; EP 19860890 A 20190910; IL 28124321 A 20210303; JP 2021512883 A 20190910; KR 20217010585 A 20190910; MX 2021002856 A 20190910; SG 11202102317P A 20190910